Literature DB >> 28240661

Molecular Imaging in Neuroendocrine Differentiation of Prostate Cancer: 68Ga-PSMA Versus 68Ga-DOTA NOC PET-CT.

Sharjeel Usmani1, Najeeb Ahmed, Fahad Marafi, Rashid Rasheed, Henney G Amanguno, Fareeda Al Kandari.   

Abstract

We report on a 62-year-old man with metastatic prostate cancer (cT3b N1) diagnosed in 2011, treated with total androgen blockage with flutamide and goserelin acetate (Zoladex). He presented with left suprascapular swelling and low-back pain after being asymptomatic for 5 years. His prostate-specific antigen was 0.049 ng/mL. F-NaF PET-CT and Ga-PSMA scan were negative, whereas Ga-DOTA NOC scan done after 10 days showed multiple somatostatin-avid hepatic and lymph node metastasis.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28240661     DOI： 10.1097/RLU.0000000000001618

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  14 in total

1.  Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Authors:  Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal:  J Nucl Med       Date:  2017-09-08       Impact factor: 10.057

Review 2.  Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases.

Authors:  Gregory A Joice; Steven P Rowe; Michael A Gorin; Phillip M Pierorazio
Journal:  Curr Urol Rep       Date:  2018-11-09       Impact factor: 3.092

Review 3.  Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.

Authors:  Shankar Siva; Cristian Udovicich; Ben Tran; Homi Zargar; Declan G Murphy; Michael S Hofman
Journal:  Nat Rev Urol       Date:  2020-01-14       Impact factor: 14.432

4.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

Review 5.  Imaging of neuroendocrine neoplasms of the male GU tract.

Authors:  Kedar G Sharbidre; Ajaykumar C Morani; Mohd Zahid; Priya Bhosale; Chandana Lall; Isaac R Francis; Sadhna Verma
Journal:  Abdom Radiol (NY)       Date:  2022-04-12

6.  Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation.

Authors:  Joel Vargas Ahumada; Sofía D González Rueda; Fabio A Sinisterra Solís; Quetzali Pitalúa Cortés; Liliana P Torres Agredo; Jimenez Ríos Miguel; Anna Scavuzzo; Irma Soldevilla-Gallardo; Miguel A Álvarez Avitia; Nora Sobrevilla; Francisco Osvaldo García Pérez
Journal:  Diagnostics (Basel)       Date:  2022-06-03

7.  Obstructive Jaundice: An Unusual Presentation of Neuroendocrine Differentiation in Prostatic Adenocarcinoma.

Authors:  Sampath Santhosh; Godwin Jeeva; Ranjan Kumar Mohapatra
Journal:  Indian J Nucl Med       Date:  2021-03-04

Review 8.  [The role of PSMA PET-CT in patients with metastatic prostate cancer].

Authors:  J von Hardenberg; K-A Büsing; P Nuhn; M Ritter
Journal:  Urologe A       Date:  2017-11       Impact factor: 0.639

Review 9.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

Review 10.  [The role of PSMA PET-CT in patients with metastatic prostate cancer].

Authors:  J von Hardenberg; K-A Büsing; P Nuhn; M Ritter
Journal:  Radiologe       Date:  2018-03       Impact factor: 0.635
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.